Gilead Sciences, Inc. (GILD) is considered one of the best blue-chip stocks to buy, with Bernstein SocGen Group setting a price target of $135. Maxim Group analyst Michael Okunewitch maintained a Hold rating, citing strong HIV sales but expressing concerns over limited growth in other areas.

In the third quarter, Gilead reported revenues of $7.8 billion, up 3% from the previous year, with earnings per share rising to $2.43. The company lifted its full-year outlook, projecting revenue between $28.4 billion and $28.7 billion, and earnings per share between $8.05 and $8.25.

Gilead Sciences, based in Foster City, California, is a biopharmaceutical company known for developing treatments for serious illnesses like HIV, viral hepatitis, and cancer. While GILD is seen as a strong investment, some suggest that other AI stocks offer greater upside potential with less downside risk.

For more insights, check out the Top 9 Undervalued Asset Management Stocks to Buy and 13 Best AI Stocks to Buy Under $20. None of the information in this article constitutes financial advice.

Read more at Yahoo Finance: Gilead Sciences, Inc. (GILD)’s Mixed Quarter Draws Divergent Analyst Views